Pyramax, a World Health Organisation-approved antimalarial drug is under clinical trial in South Korean for the treatment of COVID-19. COVID-19 was first detected in Wuhan, China at the end of 2019 and was reported to the World Health Organization (WHO) Country Office in China. Since then it is on record that no drug or vaccine has been officially approved for the treatment of COVID-19. Pyramax is a WHO prequalified artemisinin-based combination therapy for the treatment of malaria contains the active substances Pyronaridine tetraphosphate and Artesunate is presently undergoing phase 2 clinical trials for the treatment of COVID-19. But Nigeria’s National Food and Drugs Administration and Control (NAFDAC) has not approved it for the treatment of COVID-19.

Source: The Guardian June 03, 2020 17:37 UTC